Evidence map›Paper›PMID 32447422›Full record

ArticleRheumatology international2020

Management of gout by Moroccan rheumatologists: a Moroccan Society for Rheumatology National Survey.

Jihad Moulay Berkchi, Hanan Rkain, Laila Benbrahim, Souad Aktaou, Noufissa Lazrak, Souad Faiz, Samir Ahid, Redouane Abouqal, Saloua Labzizi, Naima Ouzeddoun and 4 more

Abstract read
PubMed Publisher
In one paragraph

Article in Rheumatology international, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Jihad Moulay BerkchiDepartment of Rheumatology B, El Ayachi Hospital, Faculty of Medicine and Pharmacy of Rabat, Mohammed V University, Rabat, Morocco. jihad.berkchi@gmail.com.ORCID http://orcid.org/0000-0002-8735-6880
Hanan RkainDepartment of Rheumatology B, El Ayachi Hospital, Faculty of Medicine and Pharmacy of Rabat, Mohammed V University, Rabat, Morocco.
Laila BenbrahimDay Clinic, Delegation of the Ministry of Health at the Rabat Prefecture, Rabat Regional Hospital, Rabat, Morocco.
Souad AktaouPrivate Rheumatology Clinic, Rabat, Morocco.
Noufissa LazrakPrivate Rheumatology Clinic, Rabat, Morocco.
Souad FaizDelegation of the Ministry of Health at the Prefecture of Casablanca, Casablanca, Morocco.
Samir AhidPharmacology and Toxicology Laboratory, Faculty of Medicine and Pharmacy of Rabat, Mohammed V University, Rabat, Morocco.
Redouane AbouqalLaboratory of Biostatistics, Clinical Research and Epidemiology (LBRCE), Faculty of Medicine and Pharmacy, Mohammed V University, Rabat, Morocco.
Saloua LabziziNational Nutrition Program, Direction of Population, Ministry of Public Health, Rabat, Morocco.
Naima OuzeddounDepartment of Nephrology-Hemodialysis, CHU Ibn Sina, Faculty of Medicine and Pharmacy of Rabat, Mohammed V University, Rabat, Morocco.
Latifa OukerrajDepartment of Cardiology B, Souissi Maternity, CHU Ibn Sina, Faculty of Medicine and Pharmacy of Rabat, Mohammed V University, Rabat, Morocco.
Ihsane HmamouchiLaboratory of Biostatistics, Clinical Research and Epidemiology (LBRCE), Faculty of Medicine and Pharmacy, Mohammed V University, Rabat, Morocco.
Najia Hajjaj-HassouniInternational University of Rabat, Rabat, Morocco.
Fadoua AllaliDepartment of Rheumatology B, El Ayachi Hospital, Faculty of Medicine and Pharmacy of Rabat, Mohammed V University, Rabat, Morocco.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

To assess the modalities and current practices in gout management reported by Moroccan rheumatologists. We performed a cross-sectional online survey using a questionnaire e-mailed to 360 rheumatologists included 30 multiple-choice questions. 105 rheumatologists responded to the survey with 29% of response rate. The number of gout patients seen per month was five (3-9); they were referred in 58.7% by a general practitioner. The clinical presentation of gout patients was dominated by gout crisis in 71%, and the association gout crisis and gouty arthropathy accounted for 19% of severe forms. 40% of rheumatologists apply the 2015ACR/EULAR classification criteria. Obesity accounted for 85.7% of the associated comorbidities. The most commonly prescribed Urate-lowering therapy (ULT) was allopurinol in 81.3% (± 12). 48% of rheumatologists reported starting allopurinol at 200 mg daily and associated it with colchicine during the first 6 months by 33.3%. The determination of uric acid levels was monitoring in 76.2% every 3 months. Administration of ULT to asymptomatic hyperuricemia was found in 69.5% when patients had renal complications, while only 14.3% recommended dietary and lifestyle measures. The median duration for therapeutic education was 15 min (10, 20). In 96.2%, the education of the patient was done orally. 93.3% of rheumatologists inform their patients on how to manage a gout attack, and 96.2% on the measures of hygiene and diet has adopted. Our survey gives an insight into the elements that should be improved in the management of gout by the Moroccan rheumatologists. It highlights the need to standardize the management of gout, hence the importance of developing Moroccan recommendations on gout.

Indexed as

AllopurinolColchicineCross-Sectional StudiesDrug Therapy, CombinationFemaleGoutGout SuppressantsHumansMaleMoroccoPractice Patterns, Physicians'RheumatologySurveys and QuestionnairesUric AcidAllopurinolColchicineGout SuppressantsUric AcidGoutManagementMoroccan rheumatologistSurveyUrate-lowering therapy

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.